Morphosys Finanzvorstand Jens Holstein im Interview: “Noch einmal deutlich mehr Potenzial”

Herr Holstein, im vergangenen Jahr hat Guselkumab/Tremfya die Zulassung erhalten. Derzeit laufen weitere Studien. Wie sehen sie …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
686